Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug 23:5:251-69.
doi: 10.2147/CMAR.S34273. eCollection 2013.

Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies

Mark P Chao  1
Affiliations
Review

Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies

Mark P Chao. Cancer Manag Res. .

Abstract

Over the last few decades, advances in immunochemotherapy have led to dramatic improvement in the prognosis of non-Hodgkin's lymphoma (NHL). Despite these advances, relapsed and refractory disease represents a major treatment challenge. For both aggressive and indolent subtypes of NHL, there is no standard of care for salvage regimens, with prognosis after relapse remaining relatively poor. Nevertheless, there are multiple emerging classes of targeted therapies for relapsed/refractory disease, including monoclonal antibodies, antibody- drug conjugates, radioimmunotherapy, small-molecule inhibitors of cell-growth pathways, and novel chemotherapy agents. This review will discuss treatment challenges of NHL, current available salvage regimens for relapsed/refractory NHL, and the safety and efficacy of novel emerging therapies.

Keywords: non-Hodgkin’s lymphoma; novel therapies; relapsed/refractory disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Examples of salvage therapy regimens for refractory NHL. Notes: 1Radiommunotherapy options include 131I-tositumomab and 90Y-ibritumomab tiuxetan; 2therapy for systemic ALCL, excluding primary cutaneous ALCL. Treatment options, stratification, and abbreviations are based on NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Non-Hodgkin’s Lymphomas V.1.2013. Not all treatment options included in the NCCN Guidelines are shown above. Reproduced/Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Hodgkin’s Lymphomas V.1.2013. © 2013 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. National Comprehensive Cancer Network®, NCCN®, NCCN Guidelines®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. Abbreviations: CEOP, cyclophosphamide, etoposide, vincristine, prednisone; CEPP, cyclophosphamide, etoposide, prednisone, procarbazine; CFAR, cyclophosphamide, fludarabine, alemtuzumab, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DA-EPOCH, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; DHAP, dexamethasone, cisplastine, cytarabine; DLBCL, diffuse large b-cell lymphoma; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; FCR, fludarabine, cyclophosphamide, rituximab; FCMR, fludarabine, cyclophosphamide, mitoxantrone, rituximab; FL, follicular lymphoma; FMR, fludarabine, mitoxantrone, rituximab; GDP, gemcitabine, dexamethasone, cisplatin; GemOx, gemcitabine, oxaliplatin; HyperCVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; ICE, ifosphamide, carboplatin, etoposide; MCL, mantle cell lymphoma; OFAR, oxaliplatin, fludarabine, cytarabine, rituximab; PCR, pentostatin, cyclophosphamide, rituximab; PTCL, peripheral T-cell lymphoma; R, rituximab; RFND, rituximab, fludarabine, mitoxantrone, dexamethasone; SCT, stem cell transplant.
Figure 2
Figure 2
Emerging therapeutic options in relapsed/refractory NHL. Numerous novel classes of drugs are emerging as therapeutic options in relapsed or refractory NHL. These classes include monoclonal antibodies (both next-generation anti-CD20 and non-anti-CD20 antibodies), antibody–drug conjugates, antibodies conjugated to radioactive isotopes, small-molecule inhibitors of key cell-signaling and apoptotic pathways, HDAC inhibitors, and toxicity-reducing chemotherapies. Abbreviations: abs, antibodies; Bcl-2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; HDAC, histone deacetylase; mTOR, mammalian target of rapamycin; NHL, non-Hodgkin’s lymphoma; Syk, spleen tyrosine kinase; PI3K, phosphoinositide 3-kinase.
Figure 3
Figure 3
Targeting the PI3K and BTK pathways in NHL. The B-cell receptor-signaling pathway (purple) is initiated through phosphorylation of coreceptors that recruit spleen tyrosine kinase (SYK), which then phosphorylates downstream kinases, including PLCγ, leading to activation of Bruton tyrosine kinase (BTK). BTK then binds phosphatidylinositol (3,4,5)-triphosphate (PIP3), which in turn hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers – inositol triphosphate (IP3) and diacylglycerol (DAG) – that ultimately activate downstream proteins involved in B-cell signaling. In the PI3K pathway (orange), activation of receptor tyrosine kinases (RTKs) through adaptor proteins phosphorylate subunits of PI3K, leading to conversion of PIP2 to PIP3. Phosphorylation of the tumor suppressor PTEN terminates PI3K. Accumulation of PIP3 leads to phosphorylation of AKT, which further activates downstream pathways, including mTOR (through the tuberous sclerosis complex 1/2 (TSC1/2)) and other essential pathways. Therapeutic inhibition of select pathway components that have been investigated in clinical trials for NHL are shown. Abbreviations: 4EBP-1, 4E-binding protein 1; GSK3, glycogen synthase kinase 3; mTOR, mammalian target of rapamycin; mTORC, mTOR complex; MDM2, mouse double minute 2 homolog; P, phosphorylation site; PI3K, phosphoinositide 3-kinase; PLC, phospholipase C gamma; PTEN, phosphatase and tensin homolog; RHEB, Ras homolog enriched in brain; S6K, S6 kinase.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw. 2010;8(3):288–334. - PubMed
    1. Jaffe ES, Harris NL, Stein H, Vardiman JW, World Health Organization . Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Vol. 3. Lyon: IARC; 2001.
    1. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–2045. - PMC - PubMed
    1. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823–3837. - PubMed
    1. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18(17):3135–3143. - PubMed